Christopher Bowden

Insider Reports History

Location
Cambridge, MA
Signature
/s/ Lara Meisner, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Christopher Bowden:

Company Role Class Num Shares Value Price $ Report Date Ownership
AGIOS PHARMACEUTICALS, INC. Chief Medical Officer Common stock 15,487 $335,139 $21.64 18 Jun 2021 Direct
Alaunos Therapeutics, Inc. Director Common Stock 44,167 $6,197 $0.1403 22 Jun 2022 Direct
Alaunos Therapeutics, Inc. Director Employee Stock Option (right to buy) 100,000 22 Jun 2022 Direct
Bicara Therapeutics Inc. Director Stock Option (Right to Buy) 23,746 09 Jun 2025 Direct
AGIOS PHARMACEUTICALS, INC. Chief Medical Officer Stock option (right to buy) 992 18 Jun 2021 Direct

Insider Reports Filed by Christopher Bowden

Symbol Company Period Transactions Value $ Form Type Role Filing Time
BCAX Bicara Therapeutics Inc. 09 Jun 2025 1 $0 4 Director 10 Jun 2025, 16:26
BCAX Bicara Therapeutics Inc. 12 Sep 2024 0 $0 3 Director 12 Sep 2024, 21:11
TCRT Alaunos Therapeutics, Inc. 22 Jun 2022 2 $0 4 Director 24 Jun 2022, 16:31
AGIO AGIOS PHARMACEUTICALS, INC. 18 Jun 2021 5 -$490,860 4 Chief Medical Officer 22 Jun 2021, 16:44
AGIO AGIOS PHARMACEUTICALS, INC. 17 Jun 2021 3 -$50,690 4 Chief Medical Officer 21 Jun 2021, 16:18
AGIO AGIOS PHARMACEUTICALS, INC. 09 Jun 2021 6 -$569,194 4 Chief Medical Officer 11 Jun 2021, 17:00
AGIO AGIOS PHARMACEUTICALS, INC. 07 Jun 2021 6 -$222,077 4 Chief Medical Officer 09 Jun 2021, 16:06